DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Ian Flinn , Carole Miller , Kirit Ardeshna , Scott Tetreault , Sarit Assouline , Jiri Mayer , Michele Merli , Scott Lunin , Andrew Pettitt , Zoltan Nagy , Olivier Tournilhac (1) , Karem-Etienne Abou-Nassar , Michael Crump , Eric Jacobsen , Sven de Vos , Virginia Kelly , Weiliang Shi , Lori Steelman , Ngocdiep Le , David Weaver , Stephanie Lustgarten , Nina Wagner-Johnston , Pier Luigi Zinzani

1 CHELTER - Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias

Domaines: Hématologie

Ian Flinn, Carole Miller, Kirit Ardeshna, Scott Tetreault, Sarit Assouline, et al.. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2019, 37 (11), pp.912-922. ⟨10.1200/JCO.18.00915⟩. ⟨hal-02102882⟩